Cited by 311Inflammatory Bowel DiseaseGut microbiota and healthMicroscopic Colitis

Donor species richness determines faecal microbiota transplantation success in inflammatory bowel disease

Open access
Vermeire, Severine, Joossens, Marie, Verbeke, Kristin, Wang, Jun, Machiels, Kathleen, Sabino, João, Ferrante, Marc, Van Assche, Gert +2 more·2016·Journal of Crohn s and Colitis

Abstract

BACKGROUND AND AIMS: Faecal microbiota transplantation is a successful therapy for patients with refractory Clostridium difficile infections. It has also been suggested as a treatment option for inflammatory bowel disease, given the role of the intestinal microbiota in this disease. We assessed the impact of faecal microbiota transplantation in patients with inflammatory bowel disease and studied predictors of clinical (non-)response in microbial profiles of donors and patients. METHODS: Fourteen refractory patients (8 with ulcerative colitis and 6 with Crohn's disease) underwent ileocolonoscopy with faecal microbiota transplantation through a nasojejunal (n = 9) or rectal (n = 5) tube. Efficacy was assessed by endoscopic healing at week 8, clinical activity scores and C-reactive protein measurement. Faecal microbiota was analysed by 16S rDNA pyrosequencing. RESULTS: There was no significant improvement among the 6 patients with Crohn's disease at week 8 following faecal microbiota transplantation. One patient experienced temporary clinical remission for 6 weeks. In contrast, 2/8 patients with ulcerative colitis had endoscopic remission at week 8, and of the 6 remaining patients with ulcerative colitis, 1 reported temporary remission for 6 weeks. The donor microbiota richness and the number of transferred phylotypes were associated with treatment success. Persistent increased C-reactive protein 2 weeks after transplantation was predictive of failure of response. CONCLUSION: Faecal microbiota transplantation led to endoscopic and long-term (>2 years) remission in 2 out of 8 ulcerative colitis patients. Higher donor richness was associated with successful transplant. Therefore, faecal microbiota transplantation with donor prescreening could be a treatment option for selected refractory ulcerative colitis patients.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/ecco-jcc/jjv203

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Higher donor richness was repeatedly associated with the clinical success of FMT in a nonrandomized cohort of patients with IBD refractory to medical therapy.

    “Higher donor richness was repeatedly associated with the clinical success of FMT in a nonrandomized cohort of patients with IBD refractory to medical therapy. 54,55”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Vermeire, S., Joossens, M., Verbeke, K., Wang, J., Machiels, K., Sabino, J., Ferrante, M., Van Assche, G., Rutgeerts, P., & Raes, J.
Affiliations
  • Vrije Universiteit Brussel (BE)
  • KU Leuven (BE)
  • VIB-KU Leuven Center for Microbiology (BE)
Venue
Journal of Crohn s and Colitis
Published
2015-10-29
Volume
10
Issue
4
Pages
387-394
ISSN
  • 1873-9946 (ISSN-L)
  • 1876-4479
OpenAlex
W2288187473
Cited by
311
References
50
Citations by year
2026: 8 · 2025: 16 · 2024: 26 · 2023: 26 · 2022: 36 · 2021: 29 · 2020: 46 · 2019: 39 · 2018: 31 · 2017: 30 · 2016: 23
FWCI
19.16
Type
journal article
Language
en
Open access
Locations
  • Journal of Crohn s and Colitis (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Ghent University Academic Bibliography (Ghent University) (submittedVersion)
  • Lirias (KU Leuven) (submittedVersion)
  • HighWire Press Open Archive (submittedVersion)
  • VUBIR (Vrije Universiteit Brussel) (submittedVersion)
Funders
  • Fonds Wetenschappelijk Onderzoek
  • KU Leuven
  • Vlaamse regering
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Inflammatory Bowel Disease
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Health Sciences › Medicine › Epidemiology › Microscopic Colitis
Keywords
fecal microbiota transplantation, inflammatory bowel disease
MeSH terms
Gastrointestinal Microbiome, Fecal Microbiota Transplantation, Adult, C-Reactive Protein, Colitis, Ulcerative, Colonoscopy, Crohn Disease, Female, Humans, Male, Middle Aged, Inflammatory Bowel Diseases, Treatment Outcome, Treatment Failure

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review